Between April 2002 and July 2003, 20 patients with hematological malignancies or metastatic solid tumors received an RIC allo-SCT from an HLA identical sibling in a pilot study assessing the impact of ...
Delayed-onset, grade IV neutropenia associated with rituximab therapy in a lymphoma patient: A case report and literature review No significant financial relationships to disclose. This is an ASCO ...
HOUSTON - Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from ...
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1) In a phase III, US intergroup ...
Angiogenesis, the process through which new blood vessels arise from pre-existing ones, is a focus of attention for many scientists from various fields. It is involved during embryonal development and ...
FibroGen's (NASDAQ:FGEN) oral drug roxadustat was good as recombinant erythropoietin alfa (SEPO) in improving hemoglobin (Hb) level in a phase 3 trial to treat anemia in patients receiving ...
Company will issue ordinary shares and pay $10 million upon successful Phase II trial of rHuEPO. XTL Biopharmaceuticals entered into an asset purchase agreement with Bio-GAL for the rights to a use ...
Erythropoietin treatment improves brain function, neuropsychological test scores, and electroencephalography measurements in patients with CKD. Both chronic kidney disease (CKD) and anemia may ...
Erythropoietin was no help for newborns with hypoxic-ischemic encephalopathy already undergoing therapeutic hypothermia in the phase III HEAL trial. Combined death or neurodevelopmental impairment by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results